High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10271-10279

  Liao, Weijia ^a,b   Huang, Guojin ^a   Liao, Yan ^c   Yang, Jianjun ^a   Chen, Qian ^a   Xiao, Sheng Jun ^a   Jin, Junfei ^a,b   He, Songqing ^a,b   Wang, Changming ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair   (China)

^c Ctr for Dis Contr/Prev of Guilin   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; KIF18A; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; KIF18A PROTEIN; KINESIN; MESSENGER RNA; UNCLASSIFIED DRUG; KIF18A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR THROMBUS; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; UPREGULATION;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINESIN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR BURDEN; UP-REGULATION;

EID: 84916899847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2082     Document Type: Article

References (29)

1. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822), 1245-1255.
2. Tralhão JG, Dagher I, Lino T, Roudié J, and Franco D. Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol. 2007; 33(6):746-751.
3. Kobayashi A, Kawasaki S, Miyagawa S, Miwa S, Noike T, Takagi S, Iijima S, and Miyagawa Y. Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterology. 2006; 53(71):736-741.
4. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4):253-265.
5. Malumbres M and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-166.
6. Mayr MI, Hümmer S, Bormann J, Grüner T, Adio S, Woehlke G, and Mayer TU. The human kinesin KIF18A is a motile microtubule depolymerase essential for chromosome congression. Curr Biol. 2007; 17(6):488-498.
7. Du Y, English CA and Ohi R. The kinesin-8 KIF18A dampens microtubule plus-end dynamics. Curr Biol. 2010; 20(4):374-380.
8. StumpffJ, von Dassow G, Wagenbach M, Asbury C, and Wordeman L. The kinesin-8 motor KIF18A suppresses kinetochore movements to control mitotic chromosome alignment. Dev Cell. 2008; 14(2):252-262.
9. Hartwell LH and Kastan MB. Cell cycle control and cancer. Science 1994; 266(5192):1821-1828.
10. Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang W, and Lu SH. KIF18A is involved in human breast carcinogenesis. Carcinogenesis. 2010; 31(9):1676-1684.
11. Nagahara M, Nishida N, Iwatsuki M, Ishimaru S, Mimori K, Tanaka F, Nakagawa T, Sato T, Sugihara K, Hoon DS, and Mori M. Kinesin 18A expression: clinical relevance to colorectal cancer progression. Int J Cancer. 2011; 129(11):2543-2552.
12. Rucksaken R, Khoontawad J, Roytrakul S, Pinlaor P, Hiraku Y, Wongkham C, Pairojkul C, Boonmars T, and Pinlaor S. Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark. 2012; 12(2):81-95.
13. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) met hod. Methods. 2001; 25(4):402-408.
14. Wong J and Fang G. HURP controls spindle dynamics to promote proper interkinetochore tension and efficient kinetochore capture. J Cell Biol. 2006; 173(6):879-891.
15. Oka H, Tamori A, Kuroki T, Kobayashi K, and Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994; 19(1):61-66.
16. Tandon P and Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009; 29(4):502-510.
17. Nathan H, Schulick RD, Choti MA, and Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009; 249(5):799-805.
18. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, and Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003; 237(4):536-543.
19. Wang T, Hu HS, Feng YX, Shi J, Li N, Guo WX, Xue J, Xie D, Liu SR, Wu MC, and Cheng SQ. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer. 2010; 102(11):1618-1626.
20. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, and Hsu HC. High alphafetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112(1):44-50.
21. Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, and Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011; 9:114.
22. Kow AW, Kwon CH, Song S, Shin M, Kim JM, and Joh JW. Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1222 cases of hepatectomy in a tertiary institution. Ann Surg Oncol. 2012; 19(7):2246-2255.
23. Cha C, Fong Y, Jarnagin WR, Blumgart LH, and DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003; 197(5):753-758.
24. Llovet JM, Schwartz M and Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25(2):181-200.
25. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359(19):1995-2004.
26. Zhou L, Rui JA, Wang SB, Chen SG, and Qu Q. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol. 2011; 37(6):521-525.
27. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, and Qin LX. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008; 48(6):1834-1842.
28. Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, and Yeo W. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol. 2012; 83(9):1146-1158.
29. Bhat KM and Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007; 13(10):2849-2854.